10,607 Shares in CVS Health Corporation $CVS Acquired by Mount Lucas Management LP

Mount Lucas Management LP acquired a new position in CVS Health Corporation (NYSE:CVS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,607 shares of the pharmacy operator’s stock, valued at approximately $732,000.

Several other institutional investors have also recently bought and sold shares of CVS. Vanguard Group Inc. grew its position in shares of CVS Health by 0.8% in the first quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator’s stock valued at $8,017,223,000 after purchasing an additional 969,027 shares during the last quarter. Dodge & Cox boosted its stake in CVS Health by 4.8% during the 1st quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock valued at $4,976,856,000 after purchasing an additional 3,353,223 shares during the period. Geode Capital Management LLC increased its position in CVS Health by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 28,635,233 shares of the pharmacy operator’s stock worth $1,966,083,000 after buying an additional 675,824 shares during the period. Invesco Ltd. lifted its holdings in shares of CVS Health by 13.2% during the first quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock worth $1,383,039,000 after buying an additional 2,375,764 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of CVS Health by 14.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,309,289 shares of the pharmacy operator’s stock valued at $1,037,205,000 after acquiring an additional 1,942,886 shares during the period. Institutional investors own 80.66% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Zacks Research lowered shares of CVS Health from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th. UBS Group raised their price objective on shares of CVS Health from $79.00 to $96.00 and gave the company a “buy” rating in a research report on Friday, October 24th. Barclays upped their target price on shares of CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a research report on Thursday, September 4th. Morgan Stanley boosted their price objective on shares of CVS Health from $82.00 to $89.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 14th. Finally, Baird R W raised CVS Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $89.41.

Insider Activity

In related news, Director Anne A. Finucane sold 7,500 shares of the company’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the sale, the director owned 22,156 shares in the company, valued at approximately $1,573,519.12. This represents a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.22% of the company’s stock.

CVS Health Price Performance

NYSE CVS opened at $77.86 on Monday. The stock has a market cap of $98.84 billion, a price-to-earnings ratio of 204.90, a PEG ratio of 0.87 and a beta of 0.60. CVS Health Corporation has a 52-week low of $43.56 and a 52-week high of $85.15. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.83. The business has a 50 day simple moving average of $77.70 and a 200 day simple moving average of $69.96.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.36 by $0.24. The business had revenue of $102.87 billion for the quarter, compared to analyst estimates of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period last year, the business posted $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Analysts anticipate that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd were issued a $0.665 dividend. The ex-dividend date was Thursday, October 23rd. This represents a $2.66 annualized dividend and a dividend yield of 3.4%. CVS Health’s dividend payout ratio (DPR) is presently 700.00%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.